American Chemical Society
Browse
jm7b00404_si_001.pdf (438.78 kB)

Fragment-Based Drug Discovery of Phosphodiesterase Inhibitors

Download (438.78 kB)
Version 2 2017-08-11, 18:52
Version 1 2017-08-11, 15:44
journal contribution
posted on 2017-08-11, 18:52 authored by Fredrik Svensson, Andreas Bender, David Bailey
Phosphodiesterases are proving to be fruitful targets for drug discovery. At the same time fragment-based drug discovery has matured into a powerful and widely applied technique. In this communication we review the application of fragment-based drug discovery for the successful identification of novel 3′,5′-cyclic nucleotide phosphodiesterase (PDE) inhibitors, concentrating on both experimental and computational strategies for fragment screening and hit-to-lead development. To this end, we also mine the open access databases ChEMBL and PDB for fragments showing PDE inhibitory activity, as well as SureChEMBL for recent PDE related patents, to provide a wider context for exploring fragment diversity. Together these approaches form an integrated experimental and computational platform to exploit fragment-based drug discovery for this important gene superfamily.

History